Abstract
Background: Inflammatory bowel disease (IBD) mainly consists of Crohn's disease (CD) and ulcerative colitis (UC). About 10%-15% of patients with IBD cannot be firmly diagnosed with CD or UC; hence, they are initially diagnosed as inflammatory bowel disease unclassified (IBD-U). Having a firm diagnosis is clearly preferred to guide treatment choices, and better understanding of the nature of IBD-U is required. Methods: We performed an analysis of a subset of pediatric subjects from an inception IBD cohort of patients initially enrolled in a prospective multicenter study (the RISK study). Initial diagnosis and 2-year follow-up data from the subjects diagnosed with IBD-U were analyzed. An expert panel verified final diagnosis using predefined criteria as a guide. Serological and disease-relevant ileal and rectal tissue gene expression profiles were investigated. The use and the time to initiate anti-TNFα treatment was analyzed among the outcome groups. Results: A total of 1411 subjects were enrolled with initial diagnosis of IBD, and among them, 136 subjects were initially diagnosed as IBD-U at enrollment. And 26% were reclassified as UC and 14% as CD within 2 years of diagnosis, while 60% remained as IBD-U. Of those who were reclassified, there was a 2:1 ratio, UC (n = 35) to CD (n = 19). The molecular and serological features of IBD-U at the end of follow-up were very similar to UC and very different from CD. There was less likelihood of receiving anti-TNFα agents if the diagnosis was IBD-U compared with CD (P < 0.0001). Conclusions: In our cohort, 60% of the IBD-U subjects remained as unclassified at 2 years; of those subsequently classified, a higher percentage followed a course more similar to UC. Most of the IBD-U subjects at diagnosis had serological and molecular signatures that are very similar to UC. Although the atypical presentations made the clinician to make an interim diagnosis of IBD-U, results of the molecular and serological factors performed at the time of diagnosis suggests that they were very similar to UC. However, long-term studies are needed to better understand the natural history and molecular characterization of pediatric onset IBD-U.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2285-2290 |
| Number of pages | 6 |
| Journal | Inflammatory bowel diseases |
| Volume | 24 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2018 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Gastroenterology
Cite this
}
Evolution of pediatric inflammatory bowel disease unclassified (IBD-U) : Incorporated with serological and gene expression profiles. / Chandradevan, Raguraj; Hofmekler, Tatyana; Mondal, Kajari; Harun, Nusrat; Venkateswaran, Suresh; Somineni, Hari K.; Ballengee, Cortney R.; Kim, Mi Ok; Griffiths, Anne; Noe, Joshua D.; Crandall, Wallace V.; Snapper, Scott; Rabizadeh, Shervin; Rosh, Joel R.; Walters, Thomas D.; Bertha, Madeline; Dubinsky, Marla C.; Denson, Lee A.; Sauer, Cary G.; Markowitz, James F.; LeLeiko, Neal S.; Hyams, Jeffrey S.; Kugathasan, Subra.
In: Inflammatory bowel diseases, Vol. 24, No. 10, 10.2018, p. 2285-2290.Research output: Contribution to journal › Article
TY - JOUR
T1 - Evolution of pediatric inflammatory bowel disease unclassified (IBD-U)
T2 - Incorporated with serological and gene expression profiles
AU - Chandradevan, Raguraj
AU - Hofmekler, Tatyana
AU - Mondal, Kajari
AU - Harun, Nusrat
AU - Venkateswaran, Suresh
AU - Somineni, Hari K.
AU - Ballengee, Cortney R.
AU - Kim, Mi Ok
AU - Griffiths, Anne
AU - Noe, Joshua D.
AU - Crandall, Wallace V.
AU - Snapper, Scott
AU - Rabizadeh, Shervin
AU - Rosh, Joel R.
AU - Walters, Thomas D.
AU - Bertha, Madeline
AU - Dubinsky, Marla C.
AU - Denson, Lee A.
AU - Sauer, Cary G.
AU - Markowitz, James F.
AU - LeLeiko, Neal S.
AU - Hyams, Jeffrey S.
AU - Kugathasan, Subra
PY - 2018/10
Y1 - 2018/10
N2 - Background: Inflammatory bowel disease (IBD) mainly consists of Crohn's disease (CD) and ulcerative colitis (UC). About 10%-15% of patients with IBD cannot be firmly diagnosed with CD or UC; hence, they are initially diagnosed as inflammatory bowel disease unclassified (IBD-U). Having a firm diagnosis is clearly preferred to guide treatment choices, and better understanding of the nature of IBD-U is required. Methods: We performed an analysis of a subset of pediatric subjects from an inception IBD cohort of patients initially enrolled in a prospective multicenter study (the RISK study). Initial diagnosis and 2-year follow-up data from the subjects diagnosed with IBD-U were analyzed. An expert panel verified final diagnosis using predefined criteria as a guide. Serological and disease-relevant ileal and rectal tissue gene expression profiles were investigated. The use and the time to initiate anti-TNFα treatment was analyzed among the outcome groups. Results: A total of 1411 subjects were enrolled with initial diagnosis of IBD, and among them, 136 subjects were initially diagnosed as IBD-U at enrollment. And 26% were reclassified as UC and 14% as CD within 2 years of diagnosis, while 60% remained as IBD-U. Of those who were reclassified, there was a 2:1 ratio, UC (n = 35) to CD (n = 19). The molecular and serological features of IBD-U at the end of follow-up were very similar to UC and very different from CD. There was less likelihood of receiving anti-TNFα agents if the diagnosis was IBD-U compared with CD (P < 0.0001). Conclusions: In our cohort, 60% of the IBD-U subjects remained as unclassified at 2 years; of those subsequently classified, a higher percentage followed a course more similar to UC. Most of the IBD-U subjects at diagnosis had serological and molecular signatures that are very similar to UC. Although the atypical presentations made the clinician to make an interim diagnosis of IBD-U, results of the molecular and serological factors performed at the time of diagnosis suggests that they were very similar to UC. However, long-term studies are needed to better understand the natural history and molecular characterization of pediatric onset IBD-U.
AB - Background: Inflammatory bowel disease (IBD) mainly consists of Crohn's disease (CD) and ulcerative colitis (UC). About 10%-15% of patients with IBD cannot be firmly diagnosed with CD or UC; hence, they are initially diagnosed as inflammatory bowel disease unclassified (IBD-U). Having a firm diagnosis is clearly preferred to guide treatment choices, and better understanding of the nature of IBD-U is required. Methods: We performed an analysis of a subset of pediatric subjects from an inception IBD cohort of patients initially enrolled in a prospective multicenter study (the RISK study). Initial diagnosis and 2-year follow-up data from the subjects diagnosed with IBD-U were analyzed. An expert panel verified final diagnosis using predefined criteria as a guide. Serological and disease-relevant ileal and rectal tissue gene expression profiles were investigated. The use and the time to initiate anti-TNFα treatment was analyzed among the outcome groups. Results: A total of 1411 subjects were enrolled with initial diagnosis of IBD, and among them, 136 subjects were initially diagnosed as IBD-U at enrollment. And 26% were reclassified as UC and 14% as CD within 2 years of diagnosis, while 60% remained as IBD-U. Of those who were reclassified, there was a 2:1 ratio, UC (n = 35) to CD (n = 19). The molecular and serological features of IBD-U at the end of follow-up were very similar to UC and very different from CD. There was less likelihood of receiving anti-TNFα agents if the diagnosis was IBD-U compared with CD (P < 0.0001). Conclusions: In our cohort, 60% of the IBD-U subjects remained as unclassified at 2 years; of those subsequently classified, a higher percentage followed a course more similar to UC. Most of the IBD-U subjects at diagnosis had serological and molecular signatures that are very similar to UC. Although the atypical presentations made the clinician to make an interim diagnosis of IBD-U, results of the molecular and serological factors performed at the time of diagnosis suggests that they were very similar to UC. However, long-term studies are needed to better understand the natural history and molecular characterization of pediatric onset IBD-U.
UR - http://www.scopus.com/inward/record.url?scp=85056878759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056878759&partnerID=8YFLogxK
U2 - 10.1093/ibd/izy136
DO - 10.1093/ibd/izy136
M3 - Article
C2 - 29860529
AN - SCOPUS:85056878759
VL - 24
SP - 2285
EP - 2290
JO - Inflammatory Bowel Diseases
JF - Inflammatory Bowel Diseases
SN - 1078-0998
IS - 10
ER -